TruScreen Group Limited, together with its subsidiaries, develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Central Asia, Vietnam, Zimbabwe, Indonesia, India, and the Middle East/North Africa. It offers TruScreen cervical cancer screening device, a medical device for identifying and detecting the presence of precancerous and cancerous tissue on the cervix in real time. The company was formerly known as TruScreen Limited and changed its name to TruScreen Group Limited in August 2020. TruScreen Group Limited was incorporated in 2013 and is headquartered in Auckland, New Zealand.
Price analytics
Returns
1 day
0.0%
1 week
0.0%
1 month
-16.7%
3 months
-23.1%
6 months
-28.6%
1 year
-42.9%
3 years
-58.3%
Risk
Volatility (1y ann.)
92.3%
Beta vs ASX 200
0.77
Sharpe (1y)
-0.19
VaR 95% (1-day)
-9.1%
Max drawdown (1y)
-52.6%
Off 1-year high
-47.4%
Technicals
RSI(14)
33
vs 50DMA
-14.7%
vs 200DMA
-27.7%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value61.8
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
—
Price / Book
54
Price / Sales
70
Growth87.1
Revenue growth (1y)
100
Revenue CAGR (3y)
74
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum1.3
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
6
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).